{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:30:19Z","timestamp":1790303419925,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2015,9,29]],"date-time":"2015-09-29T00:00:00Z","timestamp":1443484800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Metab Brain Dis"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1007\/s11011-015-9736-3","type":"journal-article","created":{"date-parts":[[2015,9,29]],"date-time":"2015-09-29T05:55:04Z","timestamp":1443506104000},"page":"1487-1494","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Idalopirdine \u2013 a small molecule antagonist of 5-HT6 with therapeutic potential against obesity"],"prefix":"10.1007","volume":"30","author":[{"given":"Magdalena","family":"Dudek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Marcinkowska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Bucki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Olczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Ko\u0142aczkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,9,29]]},"reference":[{"key":"9736_CR1","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1017\/S1461145710000659","volume":"13","author":"J Arnt","year":"2010","unstructured":"Arnt J, Bang-Andersen B, Grayson B, Bymaster FP, Cohen MP, DeLapp NW et al (2010) LuAE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. Int J Neuropsychopharmacol 13:1021\u20131033","journal-title":"Int J Neuropsychopharmacol"},{"key":"9736_CR2","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1038\/sj.bjp.0704030","volume":"132","author":"M Brown","year":"2001","unstructured":"Brown M, Bing C, King P, Pickavance L, Heal D, Wilding J (2001) Sibutramine reduces feeding, body fat and improves insulin resistance in dietary-obese male Wistar rats independently of hypothalamic neuropeptide Y. Br J Pharmacol 132:1898\u20131904","journal-title":"Br J Pharmacol"},{"key":"9736_CR3","unstructured":"Caldirola P (2003) 5-HT6 receptor antagonism. A novel mechanism for the management of obesity. SMI Inaugural Conference on Obesity and Related Disorders, London"},{"key":"9736_CR4","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.brainres.2006.02.129","volume":"1087","author":"S Choi","year":"2006","unstructured":"Choi S, Blake V, Cole S, Fernstrom JD (2006) Effects of chronic fenfluramine administration on hypothalamic neuropeptide mRNA expression. Brain Res 1087:83\u201386","journal-title":"Brain Res"},{"key":"9736_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pbb.2013.10.002","volume":"112","author":"KA Clissold","year":"2013","unstructured":"Clissold KA, Choi E, Pratt WE (2013) Serotonin 1A, 1B and 7 receptors of the rat medial nucleus accumbens differentially regulate feeding, water intake, and locomotor activity. Pharmacol Biochem Behav 112:1\u201317","journal-title":"Pharmacol Biochem Behav"},{"key":"9736_CR6","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/sj.bjp.0702446","volume":"126","author":"IP Connoley","year":"1999","unstructured":"Connoley IP, Liu YL, Frost I, Reckless IP, Heal DJ, Stock MJ (1999) Thermogenic effects of sibutramine and its metabolites. Br J Pharmacol 126:1487\u20131495","journal-title":"Br J Pharmacol"},{"key":"9736_CR7","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1038\/sj.bjp.0706807","volume":"148","author":"A Fisas","year":"2006","unstructured":"Fisas A, Codony X, Romero G, Dordal A, Giraldo J, Merc\u00e9 R et al (2006) Chronic 5-HT6 receptor modulation by E-6837 induces hypophagia and sustained weight loss in diet-induced obese rats. Br J Pharmacol 148:973\u2013983","journal-title":"Br J Pharmacol"},{"key":"9736_CR8","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.brainres.2008.08.012","volume":"1236","author":"A Frassetto","year":"2008","unstructured":"Frassetto A, Zhang J, Lao JZ, White A, Metzger JM, Fong TM et al (2008) Reduced sensitivity to diet-induced obesity in mice carrying a mutant 5-HT6 receptor. Brain Res 1236:140\u2013144","journal-title":"Brain Res"},{"issue":"1\u20133","key":"9736_CR9","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejphar.2010.03.026","volume":"636","author":"HH Hansen","year":"2010","unstructured":"Hansen HH, Hansen G, Tang-Christensen M, Larsen PJ, Axel AM, Raben A et al (2010) The novel triple monoamine reuptake inhibitor tesofensine induces sustained weight loss and improves glycemic control in the diet-induced obese rat: comparison to sibutramine and rimonabant. Eur J Pharmacol 636(1\u20133):88\u201395","journal-title":"Eur J Pharmacol"},{"key":"9736_CR10","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.pharmthera.2007.08.006","volume":"117","author":"DJ Heal","year":"2008","unstructured":"Heal DJ, Smith SL, Fisas A, Codony X, Buschmann H (2008) Selective 5-HT6 receptor ligands: progress in the development of a novel pharmacological approach to the treatment of obesity and related metabolic disorders. Pharmacol Ther 117:207\u2013231","journal-title":"Pharmacol Ther"},{"key":"9736_CR11","doi-asserted-by":"crossref","first-page":"124","DOI":"10.4140\/TCP.n.2014.124","volume":"29","author":"O Hilas","year":"2014","unstructured":"Hilas O, Avena-Woods C (2014) Potential role of mirtazapine in underweight older adults. Consult Pharm 29:124\u2013130","journal-title":"Consult Pharm"},{"key":"9736_CR12","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S1734-1140(13)71081-8","volume":"65","author":"M Jastrz\u0119bska-Wi\u0119sek","year":"2013","unstructured":"Jastrz\u0119bska-Wi\u0119sek M, Siwek A, Kazek G, Nawie\u015bniak B, Partyka A, Marcinkowska M et al (2013) Partial agonist efficacy of EMD386088, a 5-HT6 receptor ligand, in functional in vitro assays. Pharmacol Rep 65:998\u20131005","journal-title":"Pharmacol Rep"},{"key":"9736_CR13","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1096\/fj.04-3177fje","volume":"19","author":"O Jbilo","year":"2005","unstructured":"Jbilo O, Ravinet-Trillou C, Arnone M, Buisson I, Bribes E, Peleraux A, Penarier G, Soubrie P, Le Fur G, Galiegue S, Casellas P (2005) The Cb1 receptor antagonist rimonabant reverses the diet-induced obesity phenotype through the regulation of lipolysis and energy balance. FASEB J 19:1567\u20131569","journal-title":"FASEB J"},{"key":"9736_CR14","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/sj.ijo.0802847","volume":"29","author":"YL Liu","year":"2005","unstructured":"Liu YL, Connoley IP, Wilson CA, Stock MJ (2005) Effects of the cannabinoid Cb1 receptor antagonist Sr141716 on oxygen consumption and Soleus muscle glucose uptake in Lep(Ob)\/ Lep(Ob) mice. Int J Obes 29:183\u2013187","journal-title":"Int J Obes"},{"key":"9736_CR15","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1001\/jama.286.10.1195","volume":"286","author":"AH Mokdad","year":"2001","unstructured":"Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, Koplan JP (2001) The continuing epidemics of obesity and diabetes in the United States. J Am Med Assoc 286:1195\u20131200","journal-title":"J Am Med Assoc"},{"key":"9736_CR16","doi-asserted-by":"crossref","first-page":"282","DOI":"10.3945\/ajcn.112.055061","volume":"98","author":"R Muckelbauer","year":"2013","unstructured":"Muckelbauer R, Sarganas G, Gruneis A, Muller-Nordhorn J (2013) Association between water consumption and body weight outcomes a systematic review. Am J Clin Nutr 98:282\u2013299","journal-title":"Am J Clin Nutr"},{"key":"9736_CR17","unstructured":"Pasternak A, Szymonifka MJ (2009) Tryptamine sulfonamides as 5-ht6 antagonists. WO2009073118 A1"},{"key":"9736_CR18","doi-asserted-by":"crossref","first-page":"97S","DOI":"10.1038\/oby.2002.202","volume":"10","author":"X Pi-Sunyer","year":"2002","unstructured":"Pi-Sunyer X (2002) The obesity epidemic: pathophysiology and consequences of obesity. Obes Res 10:97S\u2013104S","journal-title":"Obes Res"},{"key":"9736_CR19","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.neulet.2010.08.011","volume":"484","author":"WE Pratt","year":"2010","unstructured":"Pratt WE, Connolly ME (2010) Contrasting effects of systemic and central sibutramine administration on the intake of a palatable diet in the rat. Neurosci Lett 484:30\u201334","journal-title":"Neurosci Lett"},{"key":"9736_CR20","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.coph.2011.01.005","volume":"1","author":"BJ Sargent","year":"2011","unstructured":"Sargent BJ, Henderson AJ (2011) Targeting 5-HT receptors for the treatment of obesity. Curr Opin Pharmacol 1:52\u201358","journal-title":"Curr Opin Pharmacol"},{"issue":"1","key":"9736_CR21","first-page":"S135","volume":"24","author":"MJ Skill","year":"2000","unstructured":"Skill MJ, Dickinson K, Jones RB, Heal DJ (2000) Thermogenic effect of chronic sibutramine treatment in female Wistar rats. Int J Obes 24(1):S135","journal-title":"Int J Obes"},{"key":"9736_CR22","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/FBP.0b013e3282d28f9c","volume":"18","author":"A Weso\u0142owska","year":"2007","unstructured":"Weso\u0142owska A, Nikiforuk A, Stachowicz K (2007) Anxiolytic-like and antidepressant-like effects produced by the selective 5-HT6 receptor antagonist SB-258585 after intrahippocampal administration to rats. Behav Pharmacol 18:439\u2013446","journal-title":"Behav Pharmacol"},{"key":"9736_CR23","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1016\/S1474-4422(14)70198-X","volume":"13","author":"D Wilkinson","year":"2014","unstructured":"Wilkinson D, Wildfeld K, Colding-Jorgensen E (2014) Safety and efficacy of idalopirdine, a 5-HT6 receptor antagonist, in patients with moderate Alzheimer\u2019s disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 13:1092\u20131099","journal-title":"Lancet Neurol"},{"key":"9736_CR24","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/S0028-3908(01)00056-9","volume":"41","author":"ML Woolley","year":"2001","unstructured":"Woolley ML, Bentley JC, Sleight AJ, Marsden CA, Fone KC (2001) A role for 5-ht6 receptors in retention of spatial learning in the Morris water maze. Neuropharmacology 41:210\u2013219","journal-title":"Neuropharmacology"},{"key":"9736_CR25","unstructured":"World Obesity Federation (2014) http:\/\/www.worldobesity.org\/aboutobesity\/ . Accessed 30 September 2014"},{"issue":"1","key":"9736_CR26","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.2013.281361","volume":"311","author":"SZ Yanovski","year":"2014","unstructured":"Yanovski SZ, Yanovski JA (2014) Long-term drug treatment for obesity a systematic and clinical review. JAMA 311(1):74\u201386","journal-title":"JAMA"},{"key":"9736_CR27","first-page":"612","volume":"61","author":"R Zi\u0119ba","year":"2007","unstructured":"Zi\u0119ba R (2007) Obesity: a review of currently used antiobesity drugs and new compounds in clinical development. Postepy Hig Med Dosw 61:612\u2013626","journal-title":"Postepy Hig Med Dosw"}],"container-title":["Metabolic Brain Disease"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-015-9736-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11011-015-9736-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11011-015-9736-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T02:29:04Z","timestamp":1567218544000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11011-015-9736-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9,29]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["9736"],"URL":"https:\/\/doi.org\/10.1007\/s11011-015-9736-3","relation":{},"ISSN":["0885-7490","1573-7365"],"issn-type":[{"value":"0885-7490","type":"print"},{"value":"1573-7365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,9,29]]}}}